Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Globe Newswire • Tue Mar 04 2025
ST. LOUIS, March 04, 2025 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded partnership with Eton Pharmaceuticals (“Eton”), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
ST. LOUIS, March 04, 2025 (GLOBE NEWSWIRE) – Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded partnership with Eton Pharmaceuticals (“Eton”), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. As part of this expanded collaboration, Optime Care will serve as the specialty pharmacy provider of a third product for Eton, dispensing the newly acquired GALZIN® (zinc acetate), an FDA-approved product used in the treatment of the ultra-rare metabolic condition of Wilson Disease.
Click here to learn more about the specialty pharmacy partnership
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.